Single Cell Dispenser device (Namocell), published in Nature Protocols.

Paper title: "Efficient and Safe Single-Cell Cloning of Human Pluripotent Stem Cells Using the CEPT Cocktail"
Minneapolis, November 17, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced the publication of a workflow study on single-cell cloning using the Single Cell Dispenser device from Namocell, a Bio-Techne brand, in Nature Protocols. The study demonstrates efficient and safe single-cell cloning of human pluripotent stem cells using the chroman 1, emricasan, polyamine, and trans ISRIB (CEPT) cocktail.

Inquiry about this news
Contact Us OnlineMore Details & Registration
Details & Registration
Related Links
Bio-Techne Press Release